Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. (1st January 2021)

• Record Type: Journal Article
• Authors: Wang, Weijia; Gellings Lowe, Nicole; Jalali, Ali; Murphy, Sean M.
• Is Part Of: Journal of medical economics. Volume 24:Number 1(2021)
• Page Start: 61
• Page End: 68
• Publication Date: 2021-01-01
• Subjects: Opioid use disorder -- prescription digital therapeutic -- therapeutic education system -- community reinforcement approach -- contingency management -- reSET-O -- healthcare resource utilization -- budget impact -- cost-effectiveness; D61 -- D81; Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.1080/13696998.2020.1858581
• Languages: English
• ISSNs: 1369-6998

Abstract

Abstract: Aims: reSET-O is a Food and Drug Administration-cleared prescription digital therapeutic (PDT) indicated to improve outpatient-treatment retention of patients with opioid use disorder (OUD). This study examined the cost-effectiveness and budget impact of reSET-O in conjunction with treatment as usual (reSET-O + TAU) relative to TAU. Materials and methods: Adult patients with ≥1 OUD diagnosis, treated with buprenorphine from 1 January 2015 to 30 March 2018, were identified from Truven Health MarketScan Commercial and Medicare Supplemental Research Databases. Twelve-week healthcare resource utilization (HCRU) costs for patients categorized as adherent and nonadherent to buprenorphine treatment were estimated. Total 12-week costs included OUD treatment and other HCRU costs. The cost-effectiveness of reSET-O + TAU was modeled in accordance with prior clinical trial outcomes. The 12-week budget impact of reSET-O was modeled for a 1 million-member healthcare plan. Results: Higher buprenorphine adherence was associated with lower HCRU costs in claims data. Twelve-week per-patient total costs were $305 more for those receiving reSET-O + TAU than those receiving TAU. The incremental cost-effectiveness ratio was $18.70 per 1 percentage-point increase in the treatment retention rate. The probability that reSET-O + TAU would be considered cost-effective was over 92% for willingness-to-pay thresholds of $6, 000 or more. The 12-week budget impact of reSET-O was $8, 908, translating to $0.003 per member per month. Limitations: The findings of the cost-effectiveness and budget impact modeling are limited by the assumptions of the models due to uncertainty around some inputs. While no model is free of bias, the inputs for this model were carefully selected to reflect contemporary treatment patterns. Conclusions: Depending on the payer's willingness to pay, reSET-O may be cost-effective in increasing buprenorphine treatment retention rates. reSET-O results in an approximate budget impact of $0.003 per member per month, depending on market share and the prevalence of the population receiving treatment for OUD.